Channing Division of Network Medicine, Brigham and Women's Hospital Harvard Medical School, Boston, MA 02115, USA.
Division of Pediatric Allergy & Immunology, Massachusetts General Hospital for Children, Boston, MA 02114, USA.
Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1590-1595. doi: 10.1016/j.bbadis.2017.02.006. Epub 2017 Feb 7.
The development of novel therapeutics and treatment regimens for the management of asthma is hindered by an incomplete understanding of its heterogeneous nature and pathophysiology. Metabolomics can provide an integrated and global profile of a biological system in a dysregulated state, making it a valuable tool to identify biomarkers along the disease development pathway and to understand the biological mechanisms driving that pathway.
Liquid chromatography-mass spectrometry metabolomic profiling was conducted on plasma samples provided at recruitment for 380 children with asthma from the 'Genetic Epidemiology of Asthma in Costa Rica Cohort'. Metabolites associated with three clinical characteristics of asthma severity (i) airway hyper-responsiveness (AHR) (ii) percent-predicted forced expiratory volume in one second/forced vital capacity ratio (FEV/FVC), and (iii) FEV/FVC post-bronchodilator were identified and their discriminatory ability assessed. Metabolite set enrichment analyses was applied to explore the biology underlying these relationships.
AHR was associated (p<0.05) with 91 of 574 metabolites (15.9%), FEV/FVC pre-bronchodilator with 102(17.8%), and FEV/FVC post-bronchodilator with 155 (27.0%). The findings suggest that these characteristics capture some common and some distinct phenotypic aspects of lung function; glycerophospholipid, linoleic acid and pyrimidine metabolism were common to all three characteristics. The corresponding metabolomic profiles showed moderate but robust discriminatory ability.
The results confirm the existence of an asthma severity metabolome. However, differences in the metabolomic profiles of the three lung function characteristics studied, suggest that refinement of both phenotype classification and metabolite selection should be a priority as the field of asthma metabolomics progresses.
由于对哮喘异质性本质和病理生理学的认识不完整,新型疗法和治疗方案的开发受到阻碍。代谢组学可以提供失调生物系统的综合和全局概况,因此是识别疾病发展途径中生物标志物并了解驱动该途径的生物学机制的有价值工具。
对来自“哥斯达黎加哮喘遗传流行病学队列”的 380 名哮喘儿童在招募时提供的血浆样本进行液相色谱-质谱代谢组学分析。鉴定与哮喘严重程度的三个临床特征相关的代谢物(i)气道高反应性(AHR)(ii)一秒用力呼气量/用力肺活量百分比(FEV/FVC)和(iii)支气管扩张后 FEV/FVC,并评估其区分能力。应用代谢物集富集分析来探索这些关系背后的生物学。
AHR 与 574 种代谢物中的 91 种(15.9%)相关(p<0.05),FEV/FVC 预支气管扩张剂与 102 种(17.8%)相关,FEV/FVC 后支气管扩张剂与 155 种(27.0%)相关。这些发现表明这些特征反映了肺功能的一些共同和一些独特的表型方面;甘油磷脂、亚油酸和嘧啶代谢与所有三个特征都有关。相应的代谢组学特征显示出中等但强大的区分能力。
这些结果证实了存在哮喘严重程度代谢组。然而,所研究的三个肺功能特征的代谢组学特征存在差异,这表明在哮喘代谢组学领域取得进展时,应优先考虑对表型分类和代谢物选择进行细化。